Related Articles
Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.
Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
Expression and clinical significance of the phosphatidylinositol 3‑kinase/protein kinase B signal transduction pathway in non‑small cell lung carcinoma
Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type